Purdue CEO outlines plans for growth away from opioid market

During the 2016 BIO-Europe Spring® partnering meeting in Stockholm, Sweden, Mark Timney, president and CEO of Purdue Pharma, caught up with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, to discuss Purdue's big plans for future business outside of opioid therapy. The pair discuss Purdue's five-year plan to build alliances with academic centers and to strike partnerships with industry peers in order to grow and evolve its portfolio to include other pain treatments and novel drugs for central nervous system disorders and other therapy areas. Purdue is not looking to follow in big pharma’s footsteps; Timney tells Ward more about its interest in specified CNS areas, such as epilepsy. He also explains why the company is seeking late-stage deals particularly and what it would take to get his attention at the discovery stage.

Interviewer: Mike Ward – Global Director of Content, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Mark Timney – President and CEO, Purdue Pharma